Coherus Oncology (CHRS) Payables (2013 - 2026)
Coherus Oncology (CHRS) posted Payables of $11.5 million for Q1 2026, up 15.77% sequentially from $9.9 million in Q4 2025, and down 82.91% YoY from $67.2 million in Q1 2025.
Coherus Oncology (CHRS) Payables (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Payables for 14 years, with the latest figure at $11.5 million in Q1 2026.
- Quarterly Payables fell 82.91% year-over-year to $11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (down 82.91% YoY) and the FY2025 annual result came in at $9.9 million, down 76.44% from the prior year.
- Payables climbed to $11.5 million in Q1 2026 per CHRS's latest filing, from $9.9 million in the prior quarter.
- Over five years, Payables peaked at $86.0 million in Q2 2024 and troughed at $9.9 million in Q4 2025.
- A 5-year average of $31.4 million and a median of $29.4 million in 2023 frame the typical range for Payables.
- The sharpest annual moves came in 2022 and 2023: Payables tumbled 92.17% in 2022, then jumped 274.02% in 2023.
- Over 5 years, Payables stood at $11.5 million in 2022, then soared by 205.56% to $35.2 million in 2023, then grew by 19.47% to $42.1 million in 2024, then sank by 76.44% to $9.9 million in 2025, then grew by 15.77% to $11.5 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $11.5 million, $9.9 million, and $24.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 35.57 Mn |
| 10 | Coherus Oncology | 219.07 Mn | 113.76 Mn | 10.07 Mn | 13.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.17 Mn |
| Mar 31, 2026 | 11.48 Mn |
| Dec 31, 2025 | 9.92 Mn |
| Sep 30, 2025 | 24.89 Mn |
| Jun 30, 2025 | 37.62 Mn |
| Mar 31, 2025 | 67.16 Mn |
| Dec 31, 2024 | 42.08 Mn |
| Sep 30, 2024 | 31.10 Mn |
| Jun 30, 2024 | 86.02 Mn |
| Mar 31, 2024 | 38.29 Mn |
| Dec 31, 2023 | 35.22 Mn |
| Sep 30, 2023 | 37.09 Mn |
| Jun 30, 2023 | 29.37 Mn |
| Mar 31, 2023 | 23.40 Mn |
| Dec 31, 2022 | 11.53 Mn |
| Sep 30, 2022 | 9.92 Mn |
| Jun 30, 2022 | 17.49 Mn |
| Mar 31, 2022 | 21.09 Mn |
| Dec 31, 2021 | 16.16 Mn |
| Sep 30, 2021 | 126.69 Mn |